News

Wellcome Trust invests a £200m VC
Enlarge image

FundingUK

Wellcome Trust invests a £200m VC

04.01.2013 - The Wellcome Trust’s new venture capital unit Syncona Partners LLC pours £200m into early stage healthcare start ups.

The world’s second largest charity plans to invest between £1m-£20m in each of its future portfolio companies as announced last spring. According to Wellcome's annual report last month, Syncona has already made one investment. The directly owned and managed investment firm combines the trust’s experience in the health and biotechnology sectors with its investment expertise. While Syncona offers a new source of finance and guidance for healthcare businesses at an early stage of their development, the trust hopes to make some return on investment to fuel its pipeline of charitable projects.

“We expect to play our part in building successful businesses based upon innovation within the life science and health-care industry,” Syncona Chief Executive Officer Martin Murphy said in a statement. According to the Trust’s annual report, its role is becoming an increasingly global one. It disclosed that UK assets now account for a mere 6% of its £14.5bn investment portfolio, down from 13% in 2009 and 33% in 2006. Hence the portfolio “has hardly suffered from the underperformance of European assets in the financial crisis.” The influential investor has also cut its assets in Europe, with the proportion of its portfolio invested in the continent falling to 13% (2009: 22%; 2006: 48%). The charity said that it envisaged better returns from faster-growing nations in Asia and Latin America.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2013-01/wellcome-trust-invests-a-pound200m-vc.html

EbolaEUFrance

30.09.2014 In the face of the Ebola outbreak sweeping the West African countries, the EMA has started to review investigational treatments for the deadly virus disease.

FinancingSwitzerlandGermanyNetherlandsFrance

26.09.2014 Biotechnology has made the news in the stock market this month, as a wave of companies announced plans to launch IPOs on European exchanges later this year.

ResearchGermany

25.09.2014 After being hit hard by the Andromeda trial data falsification scandal, German biotech Evotec is moving back into calmer waters with new MS research projects.

FinancingNetherlands

23.09.2014 Dutch Biotech VC firm Aglaia has launched a new US$65m fund targeted towards biotechnology startups working on groundbreaking technologies aimed at preventing and curing cancer.

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ADDEX3.51 CHF12.14%
  • STRATEC BIOMEDICAL41.09 EUR4.55%
  • MEDIGENE4.00 EUR2.30%

FLOP

  • CYTOS0.18 CHF-5.26%
  • MOLOGEN6.60 EUR-2.22%
  • SANTHERA86.95 CHF-1.92%

TOP

  • PAION3.22 EUR35.3%
  • CO.DON3.14 EUR28.2%
  • FORMYCON8.20 EUR16.6%

FLOP

  • CYTOS0.18 CHF-30.8%
  • EVOTEC3.10 EUR-15.8%
  • 4SC1.04 EUR-15.4%

TOP

  • SANTHERA86.95 CHF2112.5%
  • PAION3.22 EUR228.6%
  • CO.DON3.14 EUR223.7%

FLOP

  • CYTOS0.18 CHF-95.4%
  • 4SC1.04 EUR-45.0%
  • MOLOGEN6.60 EUR-44.0%

No liability assumed, Date: 30.09.2014